Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 20/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18949526 | 0.88 | NAMPT (0.64) | NAMPT | |
| SCHEMBL18949596 | 0.85 | NAMPT (0.66) | NAMPT | |
| SCHEMBL164273 | 0.85 | NAMPT (0.66) | NAMPT | |
| SCHEMBL18949529 | 0.85 | NAMPT (0.64) | NAMPT | |
| SCHEMBL160823 | 0.85 | NAMPT (0.73) | NAMPT | |
| SCHEMBL162728 | 0.83 | NAMPT (0.64) | NAMPT | |
| SCHEMBL162727 | 0.83 | NAMPT (0.64) | NAMPT | |
| SCHEMBL15372341 | 0.83 | NAMPT (0.64) | NAMPT | |
| SCHEMBL160914 | 0.83 | NAMPT (0.69) | NAMPT | |
| SCHEMBL15372334 | 0.82 | NAMPT (0.63) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676721-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2017-06-13 | — | — | US | claimed |
| EP-2611778-B1 | GUANIDINE COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM LLC (US) | 2015-08-05 | — | — | EP | claimed |
| US-20130295051-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2013-11-07 | — | — | US | claimed |
| US-9676721-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676721-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2017-06-13 | — | — | US | disclosed |
| EP-2611778-B1 | GUANIDINE COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM LLC (US) | 2015-08-05 | — | — | EP | disclosed |
| WO-2013170191-A1 | METHODS OF USING ANTAGONISTS OF NAD BIOSYNTHESIS FROM NICOTINAMIDE | GENENTECH, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20130295051-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2013-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130295051-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | NAMPT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.